Derivatives after the crash

Rosali Pretorius and Tom Harkus of Dentons consider the key objectives of Emir and their impact on the buy-side’s use of OTC derivatives

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree